CARB-X is awarding Lytica Therapeutics, Cambridge, MA, USA, up to US$5.3 million in non-dilutive funding to develop antibacterial peptides with broad activity against multidrug-resistant bacteria. The company could receive up to $11.6 million in additional funding if the project achieves certain development milestones, for a potential total of $16.9 million.
Credit: CDC
The post Lytica’s lead compounds could produce treatments for serious lung, urinary tract, and intra-abdominal infections appeared first on Healthier Environment Living Program.